48 million Americans get prescription drugs through Medicare Part D, but Medicare has had no ability to negotiate prices. A provision in the Inflation Reduction Act would change that in some cases. The bill would also cap out-of-pocket drug costs for Medicare recipients.
PhRMA CEO Steve Ubl says the group is still fighting hard against the drug pricing provisions, but is making contingency plans — and promises — should reconciliation become law.
Monkeypox doesn't carry the same urgency for Moderna as COVID, says CEO Stéphane Bancel. Though the company is working on a vaccine for the disease, it remains focused of the novel coronavirus, the flu, and ongoing expansion.
Moderna on Wednesday reported second quarter results that beat earnings and revenue expectations driven $4.5 billion in sales from its COVID -19 vaccine, but it's still the company's only commercially available product and it took a big hit on expiring shots.
Monthly Medicare premiums for "Part D" prescription drug coverage are projected to be $31.50 in 2023, down 1.8% from $32.08 this year, the Biden administration announced Friday.